Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Vaccines, Blood & Biologics

Vaccines, Blood & Biologics

                        Infectious Disease Tests


                        Fecal Microbiota Products
          Allergenics
          Blood & Blood Products
          Blood Donor Screening
          Cellular & Gene Therapy Products
          Development & Approval Process (CBER)
          Guidance, Compliance & Regulatory Information (Biologics)
          International Activities
          News & Events (Biologics)
          Resources for You (Biologics)
          Safety & Availability (Biologics)
          Science & Research (Biologics)
          Tissue & Tissue Products
          Vaccines
          Xenotransplantation Home
          Vaccines, Blood & Biologics
          CBER Rare Disease Program Frequently Asked QuestionsVaccines, Blood & Biologics CBER Rare Disease Program Frequently Asked Questions
  
  	
    Share
    Post
    Linkedin

    Email
    Print**What are the CBER development and approval processes for medical products including those for rare diseases?**
	CBER reviews Investigational New Drug Applications (INDs) and Biologics License Applications (BLAs) for biological products used in the treatment of rare diseases in accordance with federal laws including the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. CBER’s development and approval process webpageprovides a description of the various regulatory approval and notification processes, including BLAs, Premarket Approvals (PMAs), New Drug Applications (NDAs) and 510(k)s.
	**How can patients and caregivers contribute to the development and regulatory review of products for rare diseases?**
	Patient input is a critical part of CBER’s understanding of diseases and conditions. Engaging with patients and caregivers, and listening to their perspectives on their diseases and treatments, may help us advance patient-focused medical product development. CBER’s patient engagement program is committed to incorporating patient involvement in the center’s regulatory work in accordance with relevant provisions in the 21st Century Cures Act of 2016 and the Food and Drug Omnibus Reform Act of 2022 (FDORA), as well as in commitments under PDUFA VI, authorized under the Food and Drug Administration Re-authorization Act (FDARA) in 2017, and PDUFA VII, authorized in part by the FDA User Fee Reauthorization Act of 2022.  
		Furthermore, FDA offers the patient community a web platform, Patients Ask FDA, which is designed to encourage patients, caregivers, patient groups, patient advocates, and health care professionals to ask a question, request a meeting, or request a Patient Listening Session for all the FDA medical product Centers (biologics, drugs, and devices), and provide effective and efficient responses. *Note: This webform is not for industry stakeholders.*
		Learn about FDA’s Patient Engagement activities and resources at: https://www.fda.gov/patients/learn-about-fda-patient-engagement.
	**How can sponsors include patients and their advocates in regulatory meetings with the FDA?**
	Patients and their advocates possess the unique, first-hand perspective of what it is like to live with or care for an individual with a disease, and the impact of available treatments on daily life. Patients can provide valuable input into the discussion of investigational therapies by describing their experience with a disease or condition, and by defining meaningful change in terms of their specific disease and the risks they are willing to accept. CBER welcomes the participation of patients and their advocates in formal meetings related to the development of investigational products. CBER encourages sponsors to consider including patients or their advocates in their meetings with CBER and may do so by directly inviting and coordinating participation for such guests.**Where can I find information about clinical trial design for rare diseases?**

	Clinical trials are voluntary human research studies designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments. It is important to know that the FDA does not conduct Clinical Trials. You can learn more about clinical trials and how to search for a clinical trial that might be right for you at our Clinical Trials: What Patients Need to Know webpage.
		CBER also hosts an educational series, *RegenMedEd: An FDA CBER OTP Series on Regenerative Medicine*. The *RegenMedEd* series aims to bring together important stakeholders and FDA staff to discuss foundational information about regenerative medicine therapies, such as gene therapy and cell therapy products, and explore opportunities for patients, caregivers, and advocates to engage with FDA to help advance drug development. The topics for many of these events have focused on how patient and their advocates can get involved to support development of products for rare diseases.
		Additional resource: Patient Matters Video Series at https://www.fda.gov/patients/learn-about-fda-patient-engagement/patients-matter-video-series**What is an Orphan Product Designation?**

	An Orphan Product Designation is for a drug intended to treat a rare disease or condition and qualifies sponsors for various incentives to support rare disease drug development. Orphan Product Designation is granted by FDA after receipt and review of a request submitted by a sponsor to FDA’s Office of Orphan Products Development (OOPD).**Where can I find FDA funding to help advance rare disease product development?**

	CBER encourages the development and adoption of advanced technologies to modernize biopharmaceutical manufacturing. CBER has awarded several grants and contracts to support research projects to promote the development and adoption of innovative approaches for the manufacture of CBER-regulated products, including products for rare diseases. To learn more about CBER’s awarded grants and contracts visit the CBER Advanced Technologies Program Extramural Research Funding webpage. CBER solicits applications for extramural funding through the FDA Broad Agency Announcement (BAA) (SAM.gov) and the NIH Grants & Funding portal (grants.nih.gov).
		FDA’s Orphan Products Grants Program awards grants to clinical investigators to support the development of safe and effective medical products for patients with rare diseases. The program has supported clinical research since 1983 and has funded clinical trials that have facilitated the approval of more than 80 products. For more information about OOPD grant programs, visit theOOPD Grants Program webpage.**How does the standard for approval of rare disease products differ from other medical products?**

	FDA applies the same standards in reviewing and approving drugs, including biologics for rare diseases, as it does for drugs for other diseases and conditions. In reviewing a marketing application for a new drug or biologic, FDA determines whether the drug is safe and effective for its intended use. Evidence that the drug will benefit the target population should outweigh any risks and uncertainties. FDA considers flexible approaches while ensuring that statutory standards are met in the review of submissions for rare diseases. For additional information read FDA’s Draft Guidance Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. The draft guidance complements and expands on the 1998 guidance entitled “Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.” When finalized, the draft guidance will represent FDA’s current thinking on “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.”**Where can I find research by CBER staff, including research related to rare diseases?**

	CBER scientists conduct research under several mission-related programs focused on specific biologics areas such as cellular and gene therapy products, blood and blood products, and vaccines. This research broadens FDA's knowledge of fundamental biological processes and provides a robust scientific base for regulatory review. To learn more visit: https://www.fda.gov/vaccines-blood-biologics/science-research-biologics**What is a Rare Pediatric Disease Priority Review Voucher (RPD PRV)?**

	Under Section 529 to the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA will award priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria. Under this program, a sponsor who receives an approval for a drug or biologic for a "rare pediatric disease" may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product.
		For general questions concerning pediatric rare diseases or RPD PRVs, please contact the Office of Orphan Products Development at orphan@fda.hhs.gov. For questions concerning RPD PRV eligibility of biological products, contact the Center for Biologics Evaluation and Research (CBER) at industry.biologics@fda.hhs.gov.
		For additional information about RPD PRVs click here.**How do I invite a CBER rare disease expert to speak at an event?**

	CBER staff routinely present at meetings, workshops, panels, and other events. Please direct all inquiries to cberspeakerliaison@fda.hhs.gov. Information on requesting or inviting a speaker from CBER is available on our web site: FDA/CBER Speaker Request/Invitation | FDA.**How do I request a meeting with CBER and my rare disease advocacy organization?**

	Meetings between patient organizations and CBER staff present opportunities to enhance CBER’s understanding of disease burden and the impact of treatment on patients. These meetings may also help to inform efforts by patient organizations working to advance drug development such as developing or conducting natural history studies or patient input studies to support medical product development.
		To request a meeting with CBER staff, a representative from a patient organization may email CBERPatientEngagement@fda.hhs.gov. CBER will review requests and make every effort to hear directly from patient organizations according to staff availability and resources.
		For a meeting concerning a topic that applies to more than one medical product type, the request should be submitted through the Patients: Ask FDA page, which can also be used when a patient organization is unsure about which FDA center or program to contact to request a meeting with FDA.

                                                                                  Content current as of:
      08/28/2023
              
              
Regulated Product(s)
		 BiologicsVaccines, Blood & Biologics

          
                        Infectious Disease Tests


                        Fecal Microbiota Products
          Allergenics
          Blood & Blood Products
          Blood Donor Screening
          Cellular & Gene Therapy Products
          Development & Approval Process (CBER)
          Guidance, Compliance & Regulatory Information (Biologics)
          International Activities
          News & Events (Biologics)
          Resources for You (Biologics)
          Safety & Availability (Biologics)
          Science & Research (Biologics)
          Tissue & Tissue Products
          Vaccines
          Xenotransplantation
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop